Clinical trials with Soticlestat

  • CT-EU-00057186

    Enhancing seizure control: Soticlestat’s impact in Dravet and Lennox-Gastaut Syndromes

    This trial examines soticlestat as an additional therapy for children and adults with Dravet Syndrome or Lennox-Gastaut Syndrome, aiming to reduce seizure frequency. Participants, continuing their standard anti-seizure treatments, receive soticlestat tablets, with the study monitoring seizure reduction and overall health impacts, offering hope for better seizure management in these conditions.

    • Soticlestat
  • Assessing the efficiency of Soticlestat in Dravet Syndrome

    This study focuses on investigating a new medication called soticlestat for children and young individuals diagnosed with Dravet Syndrome, a rare and severe form of epilepsy. The primary objective is to determine whether this medication can effectively reduce the frequency of seizures in these young patients. Throughout the study, participants will continue with their regular anti-seizure medication while taking either the soticlestat tablet or placebo (containing no active substance) for a period of 16 weeks. Participants will be randomly assigned to receive either soticlestat or the placebo. The study will closely monitor the effectiveness and safety of the treatment, as well as its impact on the participants’ quality of life and other symptoms associated with Dravet Syndrome. After the study, participants have the option to discontinue the treatment or transition to another study if they meet the eligibility criteria.

    • Soticlestat